The Oncologist: Patient Conversation Must Include Clinical Trials

Published on: 
,

Dr. Shalaan Beg, VP of Oncology for Science 37, discusses his approach to reducing the time to trial activation at an NCI designated cancer center, how to ensure a diverse representation in clinical trials, and his opinion on decentralized and hybrid trials.

This podcast sponosored by LabVantage Soultions